Retension Pharmaceuticals Inc.

11/18/2026 | Press release | Distributed by Public on 11/18/2026 07:16

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements as of September 30, 2026, and for the three and nine months ended September 30, 2026 and 2025 and related notes included elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and related notes for the years ended December 31, 2025 and 2024 included in our final prospectus dated October 8, 2026, filed with the Securities and Exchange Commission ("SEC") under Rule 424(b)(4) of the Securities Act on October 9, 2026 (the "IPO Prospectus"). This discussion contains forward-looking statements that involve risks and uncertainties and actual results may differ materially from those anticipated. See "Special Note regarding Forward-Looking Statements" in this Quarterly Report on Form 10-Q and "Risk Factors" in the IPO Prospectus. Our historical results are not necessarily indicative of future results.

Overview

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral small-molecule phosphodiesterase-5 ("PDE-5") inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as sildenafil, were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure. RTN-001 differs from first-generation PDE-5 inhibitors as it has been specifically engineered to have increased bioavailability and an increased distribution to the muscular arteries in the body such as the aorta and its branches in the central vasculature.

In two Phase 2 pilot trials, RTN-001 achieved clinically meaningful placebo-adjusted reductions in systolic blood pressure ("SBP") and diastolic blood pressure ("DBP") in patients with hypertension and was generally well tolerated, with no drug-related serious adverse events ("SAEs") reported. We believe RTN-001 has the potential to be an effective treatment for hypertension with a favorable safety profile and thus be part of an anti-hypertensive treatment approach.

In October 2025, we initiated a randomized, multicenter, double-blind, placebo-controlled Phase 2b dose-ranging trial of a modified-release formulation of RTN-001 in adults with uncontrolled hypertension taking two to five antihypertensive medications. The primary endpoint is the change in peripheral office-seated SBP at Week 4 compared to placebo. We expect topline data in the first half of 2027.

Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, in-licensing RTN-001, establishing our intellectual property, and conducting research and development, including nonclinical and clinical testing. We have no products approved for commercial sale and have not generated any revenue from product sales. We have historically funded our operations primarily through sales of convertible preferred stock, which generated approximately $31.0 million in aggregate gross proceeds through September 30, 2026.

In connection with our initial public offering ("IPO"), on October 2, 2026 we effected a 1-for-6.21 reverse stock split of all issued and outstanding common stock and a proportional adjustment to the existing conversion ratios of each series of our convertible preferred stock then outstanding (the "Reverse Stock Split"). All share and per-share information in this Quarterly Report on Form 10-Q has been adjusted to reflect the Reverse Stock Split. In connection with the IPO, all outstanding convertible preferred stock was automatically converted into 3,774,119 shares of common stock. Following the closing of the IPO, no shares of preferred stock remain outstanding. We also restated our financial statements as of and for the year ended December 31, 2025, as described in the IPO Prospectus.

As of September 30, 2026, we had cash and cash equivalents of $9.2 million. In October 2026, we completed our IPO of 4,312,500 shares of common stock at an initial public offering price of $12.00 per share, which includes the exercise in full of the underwriters' option to purchase additional shares of our common stock. The Company received aggregate net proceeds of approximately $45.1 million after deducting underwriting discounts and commissions and offering expenses. In connection with the IPO, our common stock began trading on the Nasdaq Capital Market under the symbol "RTSN." Based on our current operating plan, management has concluded that there is no longer a substantial doubt about the

Company's ability to continue as a going concern and believes that our cash and cash equivalents will be sufficient to meet the Company's anticipated cash requirements for at least twelve months from the date the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued. We have based this estimate on assumptions that may prove wrong, and we could utilize our available capital resources sooner than we currently expect, which would have a material impact on our operations. See "- Liquidity and Capital Resources" below.

We have incurred significant operating losses since inception and expect to continue to incur substantial losses for the foreseeable future. Our net losses were approximately $5.9 million and $1.5 million for the three months ended September 30, 2026, and 2025, and approximately $13.4 million and $3.4 million for the nine months ended September 30, 2026 and 2025. We had an accumulated deficit of approximately $21.8 million as of September 30, 2026. We anticipate that our expenses and operating losses will increase substantially as we complete the Phase 2b trial, prepare for and conduct a Phase 3 trial, add personnel, protect our intellectual property, and incur the costs of operating as a public company. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for RTN-001, which may not occur for several years, if at all. If we obtain regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, manufacturing, marketing, market access and distribution.

Under the sublicense agreement (the "Redux Agreement") dated November 17, 2023 that our wholly-owned subsidiary Retension IP Holding Company, LLC ("Retension IP") entered into with Redux Therapeutics, LLC ("Redux"), we assumed the regulatory milestones royalty obligations owed by Redux to Kadmon Corporation, LLC ("Kadmon"), a subsidiary of Sanofi S.A. ("Sanofi"), under the exclusive sublicense agreement, dated February 13, 2019, as amended, by and between Kadmon and Redux (the "Kadmon Agreement"). Such royalty obligations consist of a low-teens percentage of royalties on net sales of RTN-001 and a low-teens percentage of royalties on sublicensing revenue, subject to customary deductions, to be paid each quarter in which net sales are generated or sublicense revenue is received. We cannot estimate the timing or likelihood of achieving milestones or realizing sales. For more information regarding the Redux Agreement, the Kadmon Agreement and other related agreements, see "Business - Intellectual Property - Key Agreements" in our IPO Prospectus.

As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity or debt instruments, collaborations or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed or on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our product candidate.

Components of Our Results of Operations

Operating expenses

Research and development expenses. The largest component of our operating expenses has been research and development, which is expensed as incurred and consists, or may in the future consist, primarily of: external costs under agreements with clinical research organizations ("CROs"), clinical sites and consultants to conduct our clinical trials; chemistry, manufacturing and controls costs for clinical supply; license fees and milestone payments; compensation and benefits for R&D personnel; regulatory costs; and costs of developing, prosecuting and maintaining our intellectual property. Advance payments to CROs are recorded as prepaid expenses and expensed as clinical activities are performed. We track external costs by program but do not allocate internal costs across programs. R&D expenses will increase substantially as we continue clinical development.

General and administrative expenses. G&A expenses consist primarily of compensation and benefits, including stock-based compensation, for administrative personnel and consultants, legal, accounting, audit and tax fees, insurance, and facilities and information technology costs. We expect G&A expenses to increase as we add staff and incur public-company, internal control and compliance costs.

Other income (expense)

Other income (expense) consists of interest income earned on cash and cash equivalents, and foreign exchange gains and losses.

Results of Operations

Comparison of the three months ended September 30, 2026 and 2025

​

​

​

​

​

​

​

​

​

​

​

​ ​ ​

Three Months

​ ​ ​

Three Months

​ ​ ​

​

​

​

​

Ended

​

Ended

​

​

​

(in thousands)

​

September 30, 2026

​

September 30, 2025

​

Change

Research and development

​

$

5,017

​

$

1,365

​

$

3,652

General and administrative

​

990

​

300

​

690

Total operating expenses

​

6,007

​

1,665

​

4,342

Total other income (expense), net

​

89

​

189

​

(100)

Net loss

​

$

(5,918)

​

$

(1,476)

​

$

(4,442)

​

Research and development expenses

The following table summarizes R&D expenses for the periods indicated.

​

​

​

​

​

​

​

​

​

​

​

​ ​ ​

Three Months

​ ​ ​

Three Months

​ ​ ​

​

​

​

​

Ended

​

Ended

​

​

​

(in thousands)

​

September 30, 2026

​

September 30, 2025

​

Change

Clinical trial and CRO costs (Phase 2b: CROs, sites, central laboratories)

​

$

4,096

​

$

446

​

$

3,650

CMC and drug manufacturing costs

​

138

​

172

​

(34)

Scientific consulting and advisory costs

​

322

​

556

​

(234)

Preclinical and other research and development costs

​

461

​

191

​

270

Total research and development

​

$

5,017

​

$

1,365

​

$

3,652

​

R&D expenses increased by $3.7 million, from $1.4 million to $5.0 million, primarily due to Phase 2b trial costs, which began in October 2025, partly offset by lower scientific consulting costs of $0.2 million. R&D personnel costs were $0.4 million, as we had no R&D employees in the prior-year period.

General and administrative expenses

G&A expenses increased by $0.7 million, from $0.3 million to $1.0 million, primarily due to higher personnel costs as we added administrative staff, higher stock-based compensation, recruiting fees and higher information technology costs.

Other income (expense)

Interest income decreased by $0.1 million, from $0.2 million to $0.1 million, due to lower average cash balances. There were no foreign exchange gains or losses in either period.

Comparison of the nine months ended September 30, 2026 and 2025

​

​

​

​

​

​

​

​

​

​

​

​

​ ​ ​

Nine Months

​ ​ ​

Nine Months

​ ​ ​

​

​

​ ​ ​

​

​

Ended

​

Ended

​

​

​

​

(in thousands)

​

September 30, 2026

​

September 30, 2025

​

Change

​

Research and development

​

$

11,219

​

$

2,542

​

$

8,677

​

General and administrative

​

2,575

​

1,232

​

1,343

​

Total operating expenses

​

13,794

​

3,774

​

10,020

​

Total other income (expense), net

​

351

​

413

​

(62)

​

Net loss

​

$

(13,443)

​

$

(3,361)

​

$

(10,082)

​

​

Research and development expenses

The following table summarizes R&D expenses for the periods indicated.

​

​

​

​

​

​

​

​

​

​

​

​

​ ​ ​

Nine Months

​ ​ ​

Nine Months

​ ​ ​

​

​

​ ​ ​

​

​

Ended

​

Ended

​

​

​

​

(in thousands)

​

September 30, 2026

​

September 30, 2025

​

Change

​

Clinical trial and CRO costs (Phase 2b: CROs, sites, central laboratories)

​

$

9,075

​

$

728

​

$

8,347

​

CMC and drug manufacturing costs

​

396

​

673

​

(277)

​

Scientific consulting and advisory costs

​

874

​

950

​

(76)

​

Preclinical and other research and development costs

​

874

​

191

​

683

​

Total research and development

​

$

11,219

​

$

2,542

​

$

8,677

​

​

R&D expenses increased by $8.7 million, from $2.5 million for the nine months ended September 30, 2025 to $11.2 million for the nine months ended September 30, 2026, primarily due to Phase 2b trial costs, which began in October 2025, partly offset by lower CMC and drug manufacturing costs of $0.3 million. R&D personnel costs were $0.8 million, as we had no R&D employees in the prior-year period.

General and administrative expenses

G&A expenses increased by $1.3 million, from $1.2 million for the nine months ended September 30, 2025 to $2.6 million for the nine months ended September 30, 2026, primarily due to higher personnel costs as we added administrative staff, higher stock-based compensation, recruiting fees and higher audit, tax and information technology costs, partly offset by lower corporate legal fees.

Other income (expense)

Interest income decreased by $61,000, from $413,000 to $351,000, due to lower cash balances in the third quarter of 2026. Foreign exchange gains and losses were not material in either period.

Liquidity and Capital Resources

Sources of liquidity

Since inception we have incurred significant operating losses and negative cash flows from operations and expect to continue to do so for the foreseeable future. Before our IPO, we funded operations primarily through sales of convertible preferred stock, which generated approximately $31.0 million in aggregate gross proceeds through September 30, 2026. As of September 30, 2026 and December 31, 2025, we had approximately $9.2 million and $18.9 million in cash and cash equivalents, respectively. We have not generated revenue from product sales and do not expect to in the foreseeable future, if at all.

In October 2026, we completed our IPO of 4,312,500 shares of common stock at an initial public offering price of $12.00 per share, which includes the exercise in full of the underwriters' option to purchase additional shares of our common

stock. The Company received aggregate net proceeds of approximately $45.1 million after deducting underwriting discounts and commissions and offering expenses. Our unaudited condensed consolidated balance sheet as of September 30, 2026, included elsewhere in this Quarterly Report on Form 10-Q does not reflect these net proceeds because the IPO closed after the quarter ended September 30, 2026. In connection with the IPO, our common stock began trading on the Nasdaq Capital Market under the symbol "RTSN."

Future funding requirements

Our plan of operation is to continue implementing our business strategy, continue development of RTN-001 and continue to expand our research pipeline and our internal research and development capabilities. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the clinical trials of RTN-001 and related research and development activities. In addition, we will incur additional costs associated with operating as a public company. Our future capital requirements will depend on many factors, including:

·

the scope, timing, progress, costs, and results of discovery, preclinical development, and clinical trials for RTN-001 and any future product candidates;

·

the number of clinical trials required for regulatory approval of RTN-001 and any future product candidates;

·

the costs, timing, and outcome of regulatory review of RTN-001 and any future product candidates;

·

the cost of manufacturing clinical and, if approved, commercial supplies of RTN-001 and any future product candidates; the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval;

·

the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;

·

our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement;

·

the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;

·

expenses to attract, hire and retain, skilled personnel;

·

the potential increase in the number of our employees and establishment of physical facilities to support preclinical studies and clinical trials;

·

the costs of operating as a public company, including expenses related to legal, accounting, and regulatory activities, as well as costs associated with director and officer insurance premiums, investor relations support, and maintaining compliance with exchange listing and SEC requirements;

·

our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors;

·

patients' willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;

·

the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims

·

the effect of competing technological and market developments;

·

the timing and amount of any milestone, royalty or other payments under the Redux sublicense and the related agreements;

·

the extent to which we acquire or invest in businesses, products and technologies; and

·

the impact of inflation and tariffs, as well as other factors, including economic uncertainty and geopolitical tensions, which may exacerbate the magnitude of the factors discussed above.

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate.

As of September 30, 2026, we had cash and cash equivalents of $9.2 million. In connection with the closing of our IPO in October 2026, we received aggregate net proceeds of approximately $45.1 million after deducting underwriting discounts and commissions and offering expenses. Based on our current operating plan, management has concluded that there is no longer a substantial doubt about the Company's ability to continue as a going concern and believes that our cash and cash equivalents will be sufficient to meet the Company's anticipated cash requirements for at least twelve months from the date the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued. We have based this estimate on assumptions that may prove wrong, and we could utilize our available capital resources sooner than we currently expect, which would have a material impact on our operations.

As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity or debt instruments, collaborations or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed or on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our product candidate.

Cash flows

The following table summarizes the cash flows for the periods indicated.

​

​

​

​

​

​

​

​

​

​

​

​ ​ ​

Nine Months

​ ​ ​

Nine Months

​ ​ ​

​

​

​

Ended

​

Ended

​

(in thousands)

​

​

September 30, 2026

​

September 30, 2025

​

Net cash used in operating activities

​

​

$

(9,416)

​

$

(2,543)

​

Net cash used in investing activities

​

​

-

​

-

​

Net cash provided by (used in) financing activities

​

​

(295)

​

13,774

​

Net increase (decrease) in cash and cash equivalents

​

​

$

(9,711)

​

$

11,231

​

​

Cash flows from operating activities

Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $9.4 million, primarily due to a net loss of approximately $13.4 million, adjusted for non-cash charges of $0.4 million and changes in operating assets and liabilities of $3.6 million, including prepaid clinical costs, accounts payable and accrued expenses. Net cash used in operating activities for the nine months ended September 30, 2025 was approximately $2.5 million, primarily due to a net loss of approximately $3.4 million, partly offset by changes in operating assets and liabilities of $0.7 million and non-cash charges of $0.1 million.

Cash flows from investing activities

There were no investing activities in either period.

Cash flows from financing activities

Net cash used in financing activities for the nine months ended September 30, 2026 was approximately $0.3 million, consisting primarily of payments of offering costs related to the IPO. Net cash provided by financing activities for the nine months ended September 30, 2025 was approximately $13.8 million, consisting of net proceeds from the issuance of Series B convertible preferred stock.

Contractual Obligations and Commitments

Leases.

We have no lease obligations.

Milestone and Royalty Obligations.

Under the Redux Agreement, we assumed the regulatory milestones and royalty obligations owed by Redux to Kadmon under the Kadmon Agreement. Such royalty obligations consist of a low-teens percentage of royalties on net sales of RTN-001 and a low-teens percentage of royalties on sublicensing revenue, subject to customary deductions, to be paid each quarter in which net sales are generated or sublicense revenue is received. We cannot estimate the timing or likelihood of achieving milestones or realizing sales. For more information regarding the Redux Agreement, the Kadmon Agreement and other related agreements, see "Business - Intellectual Property - Key Agreements" in our IPO Prospectus. As of September 30, 2026, no regulatory milestones had been achieved and no royalties had been paid under the Redux Agreement.

Other Obligations.

We also enter into contracts in the normal course of business with third-party CROs, clinical manufacturing organizations and clinical sites. These contracts do not contain minimum purchase commitments and are cancellable by us upon written notice.

Off-Balance Sheet Arrangements

During the periods presented we did not have, and we do not currently have, any off-balance sheet arrangements as defined in SEC rules.

Recently Issued Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially affect our financial position, results of operations or cash flows is disclosed in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Critical Accounting Estimates

Our critical accounting estimates are described in the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates" in our IPO Prospectus. There were no material changes to our critical accounting estimates as of and for the three and nine months ended September 30, 2026. Following the closing of our IPO, the fair value of our common stock used to measure stock-based awards is based on the closing price of our common stock on the Nasdaq Capital Market.

Emerging Growth Company and Smaller Reporting Company Status

The Jumpstart Our Business Startups Act (the "JOBS Act") permits an "emerging growth company" to take advantage of the extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use the extended transition period under

the JOBS Act. Accordingly, our consolidated financial statements may not be comparable to the financial statements of public companies that comply with such new or revised accounting standards. The JOBS Act also exempts us from having to provide an auditor attestation of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act.

We expect to retain our "emerging growth company" status until the earliest of: the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; the date we qualify as a "large accelerated filer," with at least $700 million of equity securities held by non-affiliates; the issuance, in any three-year period, by us of more than $1.0 billion in non-convertible debt securities; and the last day of the fiscal year ending after the fifth anniversary of our IPO.

We are also a "smaller reporting company," meaning that the market value of our stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies, which include reduced disclosure about our executive compensation arrangements and presentation of only two years of audited financial statements in addition to any required unaudited interim financial statements.

​

Retension Pharmaceuticals Inc. published this content on November 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 18, 2026 at 13:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]